---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Peptide receptor radionuclide therapy"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Peptide receptor radionuclide therapy. Topics: PRRT for hypoglycemia in metastatic insulinoma: ENETS 2023 guidance; PRRT: requirement for somatostatin receptor expression, symptomatic response, and serious adverse effects; PRRT in metastatic insulinoma: Basel single-center long-term series; Lutetium Lu 177 dotatate in malignant insulinoma: two Australian centers; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/peptide-receptor-radionuclide-therapy"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Peptide receptor radionuclide therapy

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Peptide Receptor Radionuclide Therapy

<a id="topic-2.2.2.1.7-1"></a>

### PRRT for hypoglycemia in metastatic insulinoma: ENETS 2023 guidance

> “PRRT was performed in 14 patients, 13 of whom (92.8%) had complete or partial control of hypoglycaemia syndrome”
> “In another single centre series, symptomatic response to PRRT in terms of hypoglycaemia was observed in six out of nine patients with malignant insulinoma.”
> “Consequently, both PRRT with 177Lu-DOTATATE and everolimus can be considered in advanced insulinoma cases with hypoglycaemia refractory to SSA, especially in those cases with concurrent progressive disease [4, C].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.7-2"></a>

### PRRT: requirement for somatostatin receptor expression, symptomatic response, and serious adverse effects

> “It is imperative to demonstrate expression of SSTR on the tumors using pretreatment 68Ga DOTANOC / DOTATOC / DOTATATE PET/CT”
> “Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have been obtained in small patient series with functioning metastatic gastrointestinal tract and pancreas NEN like metastatic insulinomas, even when there was no visible tumor regression”
> “However, rare (2%) but serious side effects include severe and irreversible bone marrow disease (pancytopenia, acute myelogenous leukemia, and myelodysplastic syndrome)”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.7-3"></a>

### PRRT in metastatic insulinoma: Basel single-center long-term series

> “In the long term, a total of 21 of 26 patients (81%) demonstrated improvement during the observation period”
> “The average time of benefit (improvement of hypoglycemia) was 17.2 mo (range, 0–70.2 mo), with no differences between tumor grade 1, 2, or 3”
> “In 58% of patients (15/26), a reduction of antihypoglycemic medication was achieved after PRRT during the observation period”
> “The median OS was 19.7 mo (95% CI, 6.5–32.9 mo)”
> “Of the 26 patients, 5 (19%) experienced transient hypoglycemia after injection of [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC.”

Source: [Friebe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671384/)

<a id="topic-2.2.2.1.7-4"></a>

### Lutetium Lu 177 dotatate in malignant insulinoma: two Australian centers

> “Of 15 patients (seven female; median age 60, range 26-82) treated for intractable hypoglycaemia, WHO grade (G) was known in 12 patients (three G1, six G2 and three G3).”
> “Resolution of hypoglycaemia was observed in 14/15 (93%) patients after a median of 2.5 months (range 0.2-23.5), but recurred in 7/14 cases after a median of 17.7 months (range 7.6-48.3).”
> “In all seven cases, PRRT re-treatment was successful.”
> “Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients.”

Source: [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/)

<a id="topic-2.2.2.1.7-5"></a>

### PRRT in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort

> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “PRRT demonstrated a median OS of 49.73 months.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.2.2.1.7-6"></a>

### Lutetium Lu 177 dotatate in functioning pancreatic neuroendocrine tumors including 14 insulinomas

> “Thirty-four patients with a metastatic functioning pNET (European Neuroendocrine Tumor Society grade 1 or 2) were included: 14 insulinomas, 5 VIPomas, 7 gastrinomas, and 8 glucagonomas.”
> “Subacute hematological toxicity, grade 3 or 4 occurred in 4 patients (12%) and a hormonal crisis in 3 patients (9%).”
> “71% of patients with uncontrolled symptoms had a reduction of symptoms and a more than 80% decrease of circulating hormone levels was measured during follow-up.”

Source: [Zandee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30566620/)

<a id="topic-2.2.2.1.7-7"></a>

### Lutetium Lu 177 dotatate: labeled indication

> “LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.”

Source: [Lutathera prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
